Even if GERN’s blood cancer drug has got approved today, ARDX maybe better buy, because ARDX’s two already approved and fast selling drugs had market potential at peak 3 times GERN's, and its stock market capitalization is only 2 times GERN's.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.